Develops an oral nanoparticle astaxanthin therapy (ATI-103) that embeds in mitochondrial membranes to reduce oxidative stress and restore cellular function. Targets patients with inherited mitochondrial diseases such as Friedreich’s ataxia and Leigh syndrome; features proprietary microalgae harvest and nanoparticle formulation for enhanced bioavailability and is in IND‑enabling preclinical development.